|

Liquid Biopsy Using Exosomal miRNA Enables Risk Stratification of Potential Metastasis in Patients With Intrahepatic Cholangiocarcinoma.

RECRUITINGSponsored by City of Hope Medical Center
Actively Recruiting
SponsorCity of Hope Medical Center
Started2024-06-21
Est. completion2026-06-18
Eligibility
Age18 Years+
Healthy vol.Accepted
Locations1 site
View on ClinicalTrials.gov →

NCT07224737

Summary

Occult metastasis at the time of surgery is a major driver of poor outcomes in intrahepatic cholangiocarcinoma (ICC), yet reliable preoperative biomarkers to identify such patients are lacking. The EXOMIC study aims to develop and validate a circulating exosomal microRNA (exo-miRNA)-based liquid biopsy assay to detect occult metastasis preoperatively in patients with resectable ICC.

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

* Histologically confirmed ICC (clinical stage I-III).
* Undergoing curative-intent hepatectomy.
* Availability of preoperative pasma or serum sample (≥200 µL).
* Standard staging imaging completed per institutional protocol.
* Written informed consent.

Exclusion Criteria:

* Extrahepatic cholangiocarcinoma or gallbladder cancer.
* Synchronous non-ICC malignancy.
* Inadequate clinical follow-up.
* Inability to consent.

Conditions5

CancerIntrahepatic Cholangiocarcinoma (ICC)Liver CancerLiver DiseaseLung Cancer

Locations1 site

City of Hope Medical Center
Duarte, California, 91016
Ajay Goel, PhD626-218-3452ajgoel@coh.org

Browse More Trials

Cancer trialsLung Cancer trialsLiver Disease trialsLiver Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.